Dutch biotech firm, VectorY, has raised $138m to advance its antibody technology in the treatment of neurodegenerative diseases, particularly ALS. By targeting the misfolded protein TDP-43 with antibodies, VectorY’s drug therapy could potentially tackle an aggressive form of ALS that has previously proved difficult to treat. The funding will be used to push the lead programme, VTX-002, into clinical trials which are hoped to begin in early 2025.
WhatsApp New Strict Account Settings Option to Protect Your Account from Hackers
WhatsApp has introduced Strict Account Settings, a lockdown-style security feature designed to protect users from highly sophisticated cyber-attacks. The new privacy feature is specifically tailored
